Ring 1
Ring 2
Ring 3
Ring 4

TCR² Therapeutics

Financing Rounds

  • Public
  • Exit
Round Led by Symbiosis
Round Led by Symbiosis

TCR² Therapeutics is a clinical-stage cell therapy company developing a pipeline of novel T cell therapies for cancer patients suffering from solid tumors. The company is focused on the discovery and development of product candidates against novel and complex targets utilizing its proprietary T cell receptor (TCR) Fusion Construct T cells (TRuC®-T cells). The TRuC platform is designed to specifically recognize and kill cancer cells by harnessing signaling from the entire TCR, independent of human leukocyte antigens (HLA).

View Website


  • Cell Therapy


  • Oncology

Development Status

  • Phase 2

Learn More About TCR² Therapeutics